Vicore Pharma Holding AB

VCRE · NASDAQ

$9.38−$0.94 (−9.11%)TodayMarket closed ·
Prev close $10.32

About VCRE

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

Employees
37
Headquarters
Stockholm, Vastra Gotalands
Listed
Dec 10, 2015
Sector
Health Care
Industry
Biotechnology

VCRE key statistics

Market cap
2.58B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
28.65K
Volume
28.42K
Open price
$9.70
High today
$9.80
Low today
$9.38
52 Week high
$17.80
52 Week low
$7.88

Vicore Pharma Holding AB (VCRE) at a glance

As of Oct 23, 2026, Vicore Pharma Holding AB (VCRE) shares are priced at $9.38, giving the company a market cap of 2.58B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.38 and $9.80. The current price is 0.0% above the day's low and 4.3% below its high.

Volume so far is 28.42K shares, in line with the average of 28.65K shares a day.

Over the past year Vicore Pharma Holding AB has ranged from $7.88 to $17.80, and now sits 15% of the way up that range.

Vicore Pharma Holding AB met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.51 per share against an estimate of -$0.459.

The average analyst price target is $27.58, 194.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $27.58
Low
$15.33
Now
$9.38
High
$40.38

VCRE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 16.4% on average.

  1. Q2 FY23: reported -$0.827 per share against an estimate of -$0.7245
  2. Q3 FY23: reported -$0.5643 per share against an estimate of -$0.6451
  3. Q4 FY23: reported -$0.973 per share against an estimate of -$0.5855
  4. Q4 FY24: reported -$0.40 per share against an estimate of -$0.3672
  5. Q3 FY25: reported -$0.48 per share against an estimate of -$0.4692
  6. Q4 FY25: reported -$0.54 per share against an estimate of -$0.4488
  7. Q1 FY26: reported -$0.39 per share against an estimate of -$0.4896
  8. Q2 FY26: reported -$0.51 per share against an estimate of -$0.459

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.